title: [Pneumocystis carinii pneumonia in infants with vertically acquired HIV infection in Switzerland].
abstract: OBJECTIVE
  Review of incidence, clinical picture, therapy, and outcome of Pneumocystis carinii pneumonia (PCP) in infants with vertically-acquired HIV infection in Switzerland.
  
  
  METHODS
  Inquiry among members of the Swiss Pediatrics AIDS Group, review of the data base of the Swiss Neonatal HIV Study and retrospective analysis of the charts from infants with PCP.
  
  
  RESULTS
  Since 1986 PCP has been diagnosed in 10 out of 107 infants with vertically-acquired HIV infection. PCP occurred in 7 infants at the age of 3-6 months and in 3 at the age of 9-11 months. 4 infants showed symptoms related to HIV infection before developing PCP. Before the development of PCP, infection with HIV had been ascertained in 6 infants. In 2 the diagnosis was still unclear and in the 2 remaining the risk of HIV infection was not known. None of the infants was on primary prophylaxis against PCP. Signs and symptoms of PCP included cough and tachypnea (100%) as well as high fever up to 40 degrees C (90%). Transcutaneous oxygen saturation was 70-95%. Chest X-rays revealed interstitial infiltrates in 6 infants, localized infiltrates in 2 and interstitial as well as localized infiltrates in 2. The CD4+ cell count was, with one exception, < 1500/microliters, i.e. below the normal value for age. Side effects of high dose cotrimoxazole were noted in 6 patients. 5 infants required intubation and mechanical ventilation. 4 infants died due to PCP, including 3 of those who required intubation and mechanical ventilation.
  
  
  CONCLUSIONS
  PCP in infants with vertically-acquired HIV infection preferentially occurs at the age of 3 to 6 months and is often lethal, especially in patients requiring intubation. Evaluation for HIV infection should be done as early as possible in order to introduce primary PCP prophylaxis in infants at risk for this opportunistic infection.
authors.affiliation: Universitäts-Kinderklinik Zürich.
authors.forename: C
authors.initials: C
authors.lastname: Berger
authors.forename: M
authors.initials: M
authors.lastname: Albisetti
authors.forename: S
authors.initials: S
authors.lastname: Fanconi
authors.forename: C
authors.initials: C
authors.lastname: Rudin
authors.forename: J J
authors.initials: JJ
authors.lastname: Cheseaux
authors.forename: J
authors.initials: J
authors.lastname: Micallef
authors.forename: C
authors.initials: C
authors.lastname: Kind
authors.forename: D
authors.initials: D
authors.lastname: Nadal
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications; D003131:Combined Modality Therapy; D003422:Critical Care; D005260:Female; D015658:HIV Infections / Q000175:diagnosis / Q000635:transmission*; D006801:Humans; D007223:Infant; D018445:Infectious Disease Transmission, Vertical; D008297:Male; D016720:Pneumocystis Infections / Q000150:complications* / Q000517:prevention & control / Q000628:therapy; D012189:Retrospective Studies